Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01469481 · ClinicalTrials.gov registry record · Phase 1
Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01469481: Completed Phase 1 study, sponsored by Pfizer.
NCT01469481 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01469481, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of \[14C\]PF-04991532 in healthy adult male subjects.
Interventions
- DRUG PF-04991532
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
What the finished NCT01469481 record still lists
NCT01469481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which PF-04991532 is the first listed.
NCT01469481 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01469481 about?
NCT01469481 is a clinical study titled "Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532". The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of \[14C\]PF-04991532 in healthy adult male subjects.
What is the current status of trial NCT01469481?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-11. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01469481?
The interventions under investigation include: PF-04991532 (DRUG).
Who is sponsoring clinical trial NCT01469481?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01469481's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia